Chapman, M. John

Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk

Ference, B. A., Kastelein, J. J. P., Ginsberg, H. N., Chapman, M. J., Nicholls, S. J., Ray, K. K., Packard, C. J., Laufs, U., Brook, R. D., Oliver-Williams, C., et al. (2017) · JAMA

Lipoproteins and Cardiovascular HealthGenetic Associations and Epidemiology

Cited by 304

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

Chapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 298

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

Langlois, M. R., Chapman, M. J., Cobbaert, C., Mora, S., Remaley, A. T., Ros, E., Watts, G. F., Borén, J., Baum, H., Bruckert, E., et al. (2018) · Clinical Chemistry

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 260

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 260

Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

Nordestgaard, B. G., Langlois, M. R., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 246

Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia.

Dejager, S., Bruckert, E., & Chapman, M. (1993) · Journal of Lipid Research

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 237

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk

Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 227

Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation

Chapman, M. J., Laplaud, P. M., Luc, G., Forgez, P., Bruckert, E., Goulinet, S., & Lagrange, D. (1988) · Journal of Lipid Research

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 216

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM)

Lipoproteins and Cardiovascular HealthClinical Laboratory Practices and Quality Control

Cited by 211

Plant sterols and cardiovascular disease: a systematic review and meta-analysis†

Genser, B., Silbernagel, G., De Backer, G., Bruckert, E., Carmena, R., Chapman, M. J., Deanfield, J., Descamps, O. S., Rietzschel, E. R., Dias, K. C., et al. (2012) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 209

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., et al. (2020) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 204

Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype

Twickler, T. B., Dallinga-Thie, G. M., Cohn, J. S., & Chapman, M. J. (2004) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 201

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., et al. (2018) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 200

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 192

Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues

Huby, T., Doucet, C., Dachet, C., Ouzilleau, B., Ueda, Y., Afzal, V., Rubin, E., Chapman, M. J., & Lesnik, P. (2006) · Journal of Clinical Investigation

Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

Cited by 124

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity

Didichenko, S. A., Navdaev, A. V., Cukier, A. M. O., Gille, A., Schuetz, P., Spycher, M. O., Thérond, P., Chapman, M. J., Kontush, A., & Wright, S. D. (2016) · Circulation Research

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 106

Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias

Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery

Cited by 99

Triglyceride-rich lipoproteins and remnants: targets for therapy?

Dallinga-Thie, G. M., Kroon, J., Borén, J., & Chapman, M. J. (2016) · Current Cardiology Reports

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 90

Remnant lipoproteins: are they equal to or more atherogenic than LDL?

Salinas, C. A. A., & Chapman, M. J. (2020) · Current Opinion in Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 87

LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL

Chapman, M. J., Orsoni, A., Tan, R., Mellett, N. A., Nguyen, A., Robillard, P., Giral, P., Thérond, P., & Meikle, P. J. (2020) · Journal of Lipid Research

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 65

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia

Meikle, P. J., Wong, G., Tan, R., Giral, P., Robillard, P., Orsoni, A., Hounslow, N., Magliano, D. J., Shaw, J. E., Curran, J. E., et al. (2015) · Journal of Lipid Research

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 65

Differentiating EPA from EPA/DHA in cardiovascular risk reduction

Toth, P. P., Chapman, M. J., Parhofer, K. G., & Nelson, J. R. (2022) · American Heart Journal Plus: Cardiology Research and Practice

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 33